These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 17159460

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale.
    Levine SZ, Rabinowitz J.
    J Clin Psychopharmacol; 2007 Oct; 27(5):431-6. PubMed ID: 17873671
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study.
    Hovens JE, Dries PJ, Melman CT, Wapenaar RJ, Loonen AJ.
    J Psychopharmacol; 2005 Jan; 19(1):51-7. PubMed ID: 15671129
    [Abstract] [Full Text] [Related]

  • 28. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder.
    Nolan KA, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome LL, McEvoy J, Lieberman JA.
    J Psychiatr Res; 2005 Jan; 39(1):109-15. PubMed ID: 15504429
    [Abstract] [Full Text] [Related]

  • 29. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.
    Lindenmayer JP, Khan A, Eerdekens M, Van Hove I, Kushner S.
    Eur Neuropsychopharmacol; 2007 Jan 15; 17(2):138-44. PubMed ID: 17049818
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Testosterone in first-episode schizophrenia.
    Cesková E, Prikryl R, Kaspárek T.
    Neuro Endocrinol Lett; 2007 Dec 15; 28(6):811-4. PubMed ID: 18063925
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial.
    Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Struzik L, Gendron A.
    J Anxiety Disord; 2008 Dec 15; 22(8):1480-6. PubMed ID: 18455360
    [Abstract] [Full Text] [Related]

  • 39. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y, Gibel A, Yorkov V, Ritsner MS.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct 01; 31(7):1401-9. PubMed ID: 17669574
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.